Enterprise Value
176.5M
Cash
202.6M
Avg Qtr Burn
-31.92M
Short % of Float
16.08%
Insider Ownership
50.66%
Institutional Own.
40.60%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Posoleucel Details Viral infection, Adenovirus | Phase 3 Data readout | |
Posoleucel Details Human herpesvirus 6, Epstein-Barr virus, Adenovirus, BK virus, Cytomegalovirus | Phase 3 Data readout | |
Posoleucel Details BK virus, Kidney transplantation | Phase 2 Update | |
ALVR109 Details COVID-19 | Phase 1/2 Data readout | |
ALVR106 Details Parainfluenza virus, Human metapneumovirus, Respiratory syncytial virus, Influenza | Phase 1/2 Interim update |